# Iambic Therapeutics Inc. (IAM) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $13.49, market value $639 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Iambic Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 67.8×**. Each dollar of revenue is priced at 67.8×, a level that requires very high margins or very fast growth to justify.
- **Free-cash-flow yield: -9.4%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -873.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -820.0%**. The company reported a net loss over the last twelve months.
- **Return on equity: 41.4%**. 41.4% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 22.8%**. Return on all capital, debt included, is 22.8%: comfortably above what that capital costs.
- **Return on assets: -39.6%**. Each dollar of assets produces -39.6% of profit.

## Growth
- **Revenue growth (1 yr): 689.4%**. Revenue grew 689.4% over the last year.
- **EPS growth (1 yr): -76.6%**. Earnings per share fell 76.6%, slower than revenue, so margins compressed.

## Financial health
- **Net debt / EBITDA: 2.3×**. It would take 2.3 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 6.98** (quick 6.98). Current assets cover the next year's liabilities 6.98 times.
- **Altman Z-score: -0.71**. A Z-score of -0.71 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Iambic Therapeutics Inc. does not currently pay a dividend, but it returned -0.1% of its market value through buybacks over the last year.

## Price and momentum
- **From 52-week high: -46.0%** (12.2% above the low). Trading 46% below its 52-week high, deep in a drawdown.

Live score and charts: https://foliofundamentals.com/analyzer?s=IAM · Page: https://foliofundamentals.com/stocks/iam

Not investment advice.